RxDoctor Payments Data

Mara Chambers, MD

Hematology & Oncology · Lexington, KYNPI 1639180680

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $79 of the $128 with a category attached, or 61.8%. 5 manufacturers reported payments, led by SPR Therapeutics, Inc at 51.7% of the total. 2025 is the largest year on record at $66, 6.0 times the $11 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in KY, where the typical reported total is $4,619.

$128in general payments, 2019–2025

Across 5 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$66
  • AstraZeneca$26
  • Tactile Systems Technology Inc$13
  • Gilead$12
  • Pfizer$11
$178,866in research payments, 2019–2025

Across 40 payments — averaging $4471.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$118K
  • Daiichi Sankyo Inc.$42K
  • F. Hoffmann-la Roche AG$19K

What the payments were for

  • Food & beverage$7962%
  • Education$4938%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$128 in reported general payments places this provider in the 0th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,419
Medicare patients
162
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib31$440,738
VerzenioAbemaciclib25$341,968
OrserduElacestrant Hcl17$341,235
KisqaliRibociclib Succinate13$161,739
Everolimus11$43,103
Anastrozole493$10,059
EliquisApixaban14$9,398
Exemestane29$6,004
Ondansetron Hcl19$5,815
Letrozole125$2,062
Oxycodone Hcl24$723
Morphine Sulfate22$515
Tamoxifen Citrate13$473
Prochlorperazine Maleate30$395
Dexamethasone16$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$11$450,13645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →